Ultra leaf purified anti mouse cd20

Female heterozygous ARE-Del ^+/− mice were generated by crossing male homozygous ARE-Del ^−/− mice [29 (link),30 (link)] with female wild type B6 mice. Mice were housed in specific pathogen free conditions at the University of California, Davis vivarium. 12 weeks old female ARE--Del^+/− were randomly divided into four experimental groups and intraperitoneally (IP) administrated with either phosphate buffered saline (PBS, controls), anti-BAFF alone, anti-CD20 alone or anti-BAFF in combination with anti-CD20 mAbs. Anti-BAFF (10F4, GlaxoSmithKline, GSK), a neutralizing recombinant hybridoma monoclonal antibody raised against a mouse BAFF protein produced in Armenian Hamster cell line (No Hamster material present). Anti-BAFF was administered at 100 mcg (5 mg/kg) three times a week, anti-CD20 (Ultra-LEAF^™ purified anti-mouse CD20, BioLegend) was administered at 250 mcg (12.5 mg/kg) once every 4 weeks for a total of 12 weeks. Serum immunoglobulin (Ig) G, IgA, IgM, AMA levels and inflammatory cytokine levels were monitored every 4 weeks. All studies were conducted in accordance with the University of California, Davis and the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals and were reviewed and approved by the Institutional Animal Care and Use Committee at GSK and the University of California Animal Care and Use Committee.